Astellas Pharma Inc - Common Stock - Foreign

Historical Holders from Q1 2014 to Q3 2025

Type / Class
Equity / Common Stock - Foreign
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
1,068,236
Holdings value
$11,561,164
% of all portfolios
0%
Number of holders
2
Number of buys
1
Average buys %
+0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of Astellas Pharma Inc - Common Stock - Foreign

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 1,068,236 $11,561,164 +$225,391 $10.83 2
2025 Q2 1,047,410 $10,302,658 +$927,136 $9.82 2
2025 Q1 953,155 $9,192,352 +$264,293 $9.66 2
2024 Q4 925,750 $9,028,394 +$518,762 $9.76 2
2024 Q3 872,557 $9,999,246 +$260,907 $11.49 2
2024 Q2 849,789 $8,398,073 +$3,311,260 $9.88 2
2024 Q1 514,727 $5,526,011 +$125,380 $10.8 2
2023 Q4 503,047 $6,015,167 +$5,954,175 $11.96 2
2023 Q3 5,100 $70,882 -$225,243 $13.9 1
2023 Q2 20,224 $301,072 -$42,665 $14.88 2
2023 Q1 23,095 $327,233 -$1,084,373 $14.17 2
2022 Q4 99,739 $1,517,865 -$1,642,095 $15.25 2
2022 Q3 227,383 $3,010,993 $13.24 2
2022 Q2 227,383 $3,540,352 +$186,817 $15.57 2
2022 Q1 215,383 $3,390,812 $15.74 2
2021 Q4 215,383 $3,498,672 +$144,289 $16.24 2
2021 Q3 206,500 $3,410,246 -$262,580 $16.51 2
2021 Q2 222,400 $3,876,770 $17.43 2
2021 Q1 222,400 $3,425,163 +$924,163 $15.4 2
2020 Q4 162,400 $2,507,000 $15.44 1
2020 Q3 162,400 $2,411,000 +$774,964 $14.85 1
2020 Q2 110,200 $1,838,000 +$266,000 $16.68 1
2020 Q1 101,175 $1,572,000 -$121,192 $15.54 1
2019 Q4 108,975 $1,876,000 -$139,441 $17.22 1
2019 Q3 117,075 $1,666,000 +$4,269 $14.23 1
2019 Q2 116,775 $1,662,000 -$4,763,774 $14.23 1
2019 Q1 451,486 $6,754,000 +$160,067 $14.96 1
2018 Q4 440,786 $5,620,000 -$6,375 $12.75 1
2018 Q3 441,286 $7,692,000 -$367,617 $17.43 1
2018 Q2 462,376 $7,051,000 +$338,539 $15.25 1
2018 Q1 440,176 $6,685,000 -$1,086,091 $15.19 1
2017 Q4 511,690 $6,527,000 +$8,929 $12.76 1
2017 Q3 510,990 $6,498,000 +$6,498,000 $12.72 1
2016 Q4 0 $0 -$17,002,325 0
2016 Q3 1,105,190 $17,002,325 -$29,523 $15.54 3
2016 Q2 1,107,090 $17,094,556 -$10,106,224 $15.6 3
2016 Q1 1,755,100 $23,222,405 +$1,822,790 $13.31 3
2015 Q4 1,618,200 $23,133,733 -$184,472,172 $14.39 3
2015 Q3 15,919,213 $205,220,142 -$206,568,678 $12.9 3
2015 Q2 16,093,928 $229,418,157 -$69,762,267 $14.26 3
2015 Q1 20,984,490 $344,093,180 +$223,286 $16.41 3
2014 Q4 20,970,880 $294,832,155 +$22,274,292 $14.07 3
2014 Q3 19,387,380 $288,451,164 +$47,575,070 $14.89 3
2014 Q2 16,191,580 $212,590,145 +$13,331,612 $13.14 3
2014 Q1 15,165,920 $180,250,000 +$151,055,621 $11.89 1